We provide evidence that risk aversion leads pharmaceutical firms to underinvest in radical andnovel innovation. We do …, reducing their willingness to investin potentially valuable radical innovation …

. Among others, countries like the UK, Switzerland, Germany, the Netherlands, and Denmark established science and innovation … diplomacy agencies. We comparatively examine three cases: The UK's Science and Innovation Network, the Swiss SWISSNEX, and the … Danish Innovation Centre Denmark. We look for similarities and dissimilarities in terms of organisational setup, locations …